
Inside Illinois’ First Psychedelics Bill: How Advocates Are Breaking the Taboo
PolicyPsychedelic advocates are preparing to present Illinois' first-ever policy reform bill, but before they do, they need public support.

Psychedelics Movement Marches Forward in These 4 US States
PolicyAnother Michigan city decriminalizes psychedelic plants and fungi, while Maryland passes a bill to provide military veterans with cost-free access to healing medicines like ketamine, psilocybin, and MDMA.

Oregon Psilocybin Rules ‘May Have a Negative Impact on Lower Income Individuals’
PolicyThe State acknowledges proposed psilocybin services rules will incur costs that "could ultimately be passed onto clients."

Oklahoma House Passes Psilocybin Decriminalization Bill
PolicyNow it's up to the state's Senate to consider the bill decriminalizing the possession of psilocybin and authorizing research.

The Road to Psychedelics Legalization
PolicyMatthew X. Lowe, Ph.D., the Research Director of Unlimited Sciences, explains why observational research is the key for eventual legalization of psychedelic drugs.

When Will Psilocybin Be Available in Oregon and What’s the Hold-Up?
PolicyThe Oregon Health Authority has until December 31, 2022, to finalize the framework, paving the way for licensure in early 2023.

Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics
PolicyBiotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.

Oregon Psilocybin Advisory Board Proposes Legalizing Just One Species of Psychedelic Fungi
Policy"These fungi pose less potential safety risks to consumers," says Psilocybin Advisory Board mycologist Jessie Uehling.

Maine CDC Director Opposes Bill to Legalize Therapeutic Psilocybin
PolicyOne of Dr. Nirav Shah's chief concerns with the bill is proposed "Psilocybin Service Centers," which he fears will lean recreational instead of medical.

How Psychedelic Treatment Through Canada’s SAP Works
PolicyTwo psychedelic industry insiders reflect on the progress and flaws within Health Canada's recent amendment to the Special Access Program.